Richard I. Fisher, M.D.

See information for Patients. Viewing information for Researchers.

Richard I. Fisher, M.D. is a visionary that never loses sight of his patients. His greatest desire as Director of the Wilmot Cancer Center is to build a world-class cancer research and treatment facility that will provide advanced care and the most modern treatments for patients with cancer. With great concern and enthusiasm, he intends to ensure that patients get cutting-edge care as our cancer research program develops the treatments that will benefit patients around the world.

Dr. Fisher is an internationally known expert in biological research and treatment of lymphoma and is a nationally renowned cancer clinician, scientist and educator. His research centers on the biology and treatment of cancers derived from white blood cells. Dr. Fisher leads both national and international studies in Hodgkin's Disease and Non-Hodgkin's lymphoma.

Contact:

Richard I. Fisher, M.D.

University of Rochester Cancer Center

601 Elmwood Avenue

Box 704

Rochester, NY 14642

For referrals, call 1-866-4WILMOT

Current Appointments

• Director, Univ. of Rochester Medical Faculty Group - Department of Office of VP for Health Sciences (URMC)
• Vice President, URMC - Department of Office of VP for Health Sciences (URMC)
• Senior Associate Dean, Clinical Affairs - Department of Dean's Office, SMD (SMD)
• Director - Cancer Center (SMD)
• Samuel E. Durand Chair in Medicine - Department of Medicine (SMD)
• Professor - Department of Medicine (SMD)

Education
MD Medicine	Harvard Medical School	1970
Chemistry	Harvard University	Attended: 1963 - 1966

Post-Doctoral Training & Residency
Oncology Fellowship Medicine Branch National Cancer Institute Bethesda, Maryland	1974 - 1975
Clinical Associate Immunology Branch National Cancer Institute (Public Health Service) Bethesda, Maryland	1972 - 1974
Associate Resident in Medicine Massachusetts General Hospital Boston, Massachusetts	1971 - 1972
Internship Massachusetts General Hospital Boston, Massachusetts	1970 - 1971

Board Certifications
Diplomate, Subspecialty of Oncology, American Board of Internal Medicine	1977
Diplomate, American Board of Internal Medicine	1973
Diplomate, National Board of Medical Examiners	1971

Recent Journal Articles
Showing the 5 most recent journal articles. (274 available)
Hilchey, S.P.; Hyrien, O.; Mosmann, T.R.; Livingstone, A.M.; Friedberg, J.W.; Young, F.; Fisher, R.I.; Kelleher Jr., R.J.; Bankert, R.B. and Bernstein, S.H. "Rituximab Immunotherapy Results in the Induction of a Lymphoma Idiotype-Specific T-Cell Response in Patients with Follicular Lymphoma: Support for a "Vaccinal Effect" of Rituximab." Blood (2009).
Dasmahapatra, G.; Lembersky, D.; Rahmani, M.; Kramer, L.; Friedberg, J.; Fisher, R.I.; Dent, P., and Grant, S. "Bcl-2 Antagonists Interact Synergistically with Bortezomib in DLBCL Cells in Association with JNK Activation and Induction of ER Stress." Cancer Biology & Therapy 8 (2009): 1-12.
Goy, A.; Berstein, S.H.; Kahl, B.S.; Djulbegovic, B.; Robertson, M.J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lonial, S.; Nasta, S.; O'Connor, O.A; Shi, H.; Boral, A.L.; Fisher, R.I. "Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Time-To-Event Analyses of the Multicenter Phase 2 PINNACLE Study." Annals of Oncology 20 (2009): 520-525.
Stopeck, A.T.; Unger, J.; Rimsza, L.M.; Bellamy, W.T.; Iannone, M.; Persky, D.O.; LeBlanc, M.; Fisher, R.I. and Miller, T.P. "A Phase II Trial of Single Agent Bevacizumab in Patients with Relapsed, Aggressive Non-Hodgkin Lymphoma; Southwest Oncology Group Study S0108." Leukemia and Lymphoma 50 (2009): 728-735.
Friedberg, JW; Kelly, J; Neuberg, D; Peterson, D; Kutok, JL; Salloum, R; Brenn, T; Fisher, DC; Ronan, E; Dalton, V; Rich, L; Marquis, D; Rothberg, P; Liesveld, J; Fisher, RI; Coffman, R; Mosmann, T; Freedman, AS. "Phase II study of a TLR-9 agonist (1018 ISS) with Rituximab in patients with relapsed or refractory follicular lymphoma". Brit J Heme 146 (2009): 282-291.